Scott T. Rottinghaus - Dec 5, 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: Chief Medical Officer
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Stock symbol: ENTA
Transactions as of: Dec 5, 2025
Transactions value $: -$11,356
Form type: 4
Date filed: 12/5/2025, 06:46 PM
Previous filing: Nov 26, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rottinghaus Scott T.	Chief Medical Officer	C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN	/s/ Matthew Kowalsky as attorney-in-fact	2025-12-05	0001942407

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTA	Common Stock	Sale	-$11.4K	-798	-3.53%	$14.23	21.8K	Dec 5, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Content

Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.